Mucosal pathogens recognise glycoconjugate receptors at the site of infection, and attachment is an essential first step in disease pathogenesis. Inhibition of attachment may thus prevent disease, and several approaches have been explored (Fig. 1) . This review discusses the prevention of bacterial attachment and disease by agents that modify the glycosylation of cell surface glycoconjugates. The glycosylation inhibitors were tested in the urinary tract infection model, where P fimbriated Escherichia coli rely on glycosphingolipid receptors for attachment and tissue attack. NB-DNJ blocked the expression of glucosylceramidederived glycosphingolipids and attachment was reduced. Bacterial persistence in the kidneys was impaired and the inflammatory response was abrogated. NB-DNJ was inactive against strains, which failed to engage these receptors, including type 1 fimbriated or non-adhesive strains. In previous studies, in vivo attachment was successfully prevented by soluble receptor analogues, but there is little clinical experience of such inhibitors. Large-scale synthesis of complex carbohydrates, which could be used as inhibitors of attachment, remains a technical challenge.
Introduction
Many pathogenic microbes rely on glycoconjugate receptors for their interaction with the host (Källenius et al., 1980; Leffler & Svanborg-Edén, 1980; Mirelman, 1986) . They have evolved to take advantage of the structural variation among glycoconjugates on host cells by using them as receptors at the site of infection. This mechanism allows for microbial specificity, due to the variation in oligosaccharide structure with the species, individual and tissue. Mucosal pathogens, engage epithelial cell glycoconjugates for attachment to the mucosa and to initiate tissue attack. The epithelial cells in the mucosal barrier are highly glycosylated, and the microbial lectins bind oligosaccharide epitopes on glycolipids or glycoproteins. In glycolipids, the oligosaccharides are bound to ceramide, which spans the outer leaflet of the lipid bilayer but in glycoproteins, the oligosaccharides are covalently linked to membrane bound or soluble proteins. Cholera toxin binds to members of the ganglioseries of glycolipids in the intestine and bacterial adhesins in the respiratory tract show similar specificity (Scharfman et al., 1996; van Heyningen & King, 1976) . Glycolipids of the globoseries act as receptors for P fimbriae and shiga toxin (Leffler & Svanborg-Edén, 1980; Lingwood et al., 2000) . Mannosylated glycoproteins have been identified as receptors for type 1 fimbriae and sialylated structures are recognised by S fimbriae (Aronson et al., 1979; Korhonen et al., 1986; Ofek et al., 1977) .
Uropathogenic Escherichia coli (E. coli) exemplify a large number of mucosal pathogens that bind to glycoconjugate receptors on epithelial cells (Leffler & Svanborg-Edén, 1980; Svanborg Eden, 1980) . We have studied P fimbriae and the globoseries of glycosphingolipids (GSLs) as a model of receptor specific interactions between pathogen and host. When these studies were initiated, microbial adherence was thought to rely on non-specific forces like charge and hydrophobicity, but such mechanisms were not compatible with the host and tissue specificity of disease. Guided by the specificity for urinary tract epithelial cells, we identified the globoseries of GSLs as receptors for P fimbriated E. coli (Leffler & Svanborg-Edén, 1980) ( Fig. 2) . Three main criteria were used to define the receptor specificity. First, the isolated glycolipid was shown to be necessary and sufficient for fimbrial binding. Coating of inert surfaces like silica plates with receptor glycolipids enabled these surfaces to specifically bind P fimbriated bacteria. The binding was later shown to depend on the PapG protein, which is the tip adhesin of P fimbriae (Lindberg et al., 1986; Lindberg et al., 1984; Lund et al., 1987) .
Second, the attachment of P fimbriated bacteria was inhibited by the soluble receptor glycolipid (Leffler & Svanborg-Edén, 1980) . This approach was efficient also in vivo as shown by the administration of soluble receptor analogues and the resulting prevention of infection in the murine urinary tract (Svanborg-Edén et al., 1982) . Third, genetic variation in receptor expression was shown to influence the attachment to intact human epithelial cells (Marcus et al., 1981) . The majority of individuals belong to blood group P1 (75%) or P2 (24%) and express the globoseries of glycolipids on epithelial cells in the bladder, renal pelvis and tubuli but individuals of blood group p lack the globoseries of GSLs, due to an enzyme deficiency that precludes the elongation of the carbohydrate chains (Holgersson et al., 1992; Lomberg et al., 1981) . Cells from p individuals were shown not to bind P fimbriated E. coli, and extracted GSLs from p individuals lacked receptor activity either after binding to silica plates or when used as soluble inhibitors (Bock et al., 1985; Leffler & Svanborg-Edén, 1980 ). The epithelial glycolipids structure is further defined by the secretor state (Lomberg et al., 1986; Stapleton et al., 1992) .
Inhibition of glycosphingolipid expression
A schematic of glycosphingolipid (GSL) biosynthesis is shown in (Fig. 3) . Ceramide is formed by the condensation of palmitoyl-CoA with serine to generate 3-ketodihydrosphingosine in a reaction catalysed by serine palmitoyl-transferase. The fatty acids are coupled to sphinganine through fatty acyl CoA sphinganine forming ceramide (Radin, 1984) . Ceramide can either form sphingomyelin by coupling of phosphoryl-choline to the primary hydroxyl group of ceramide or GSLs by the action of a ceramide specific glucosyltransferase. Most GSLs are generated by the action of N-acylsphingosine glucosyltransferase which couples glucose (from UDP-glucose) to glucosyl-ceramide (GlcCer) (Platt & Butters, 1995; Shayman & Radin, 1991) .
Several types of chemical GSL biosynthesis inhibitors have been developed. Inhibition of ceramide biosynthesis may be achieved using Fumonisins but the active components are toxic and carcinogenic. The Fumonisins are produced by Fusarium verticillioides, a common fungal contaminant of maize (Marasas et al., 2004; Norred et al., 1992) . Ceramide glycosylation may be blocked either at the UDP-binding site on ceramide or at modifying sites on the enzyme itself (Inokuchi & Radin, 1987; Inokuchi et al., 1989; Platt & Butters, 1995) . Two main classes of glucosyltransferase inhibitors have been described, the PDMPseries and the N-alkylated imino sugars. The cationic lipid D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) is a ceramide mimetic (Inokuchi & Radin, 1987; Radin et al., 1993) . PDMP has been shown to reduce cell growth in vitro, in the kidneys of mice and in cancer cells and to block proliferative responses to lymphocyte mitogens (Inokuchi et al., 1987; Inokuchi et al., 1989) . The MDCK cell line showed increased levels of free ceramide and diglycerides after GSL depletion by PDMP (Shayman & Radin, 1991) . The second generation of PDMP derivatives such as the P4 compound can be tolerated in vivo in the mouse (Abe et al., 2000) .
The imino-sugar deoxynojirimycin (DNJ) occurs naturally in plants, fungi and bacteria, and is better tolerated than other glycosylation inhibitors (Platt & Butters, 2004) . It probably forms a part of a chemical defence strategy against other competing organisms in the same ecological niche. A derivative of DNJ, N-butyldeoxynojirimycin (NB-DNJ) blocks the N-linked oligosaccharide processing enzymes α-glucosidases I and II and inhibits the activity of ceramide glucosyltransferase, resulting in the inhibition of GSL biosynthesis (Platt & Butters, 1995; Receptor depletion and lipid storage disease NB-DNJ is an orally available compound and has been used successfully as a therapeutic agent in a GSL lysosomal storage disease, Gaucher disease. This is a genetic disorder characterised by deficient glucocerebrosidase activity leading to the accumulation of Glc-Cer, particularly in macrophages (Platt & Butters, 2004; Platt, 1998 Platt, , 1997 . The patients suffer severe hypertrophy of the spleen and liver, haematological abnormalities and bone disease. In addition, these patients have an unexpectedly high incidence of leukemia and other B-cell disorders. Using a murine macrophage cell line, an in vitro model was created by inhibiting glucocerebrosidase (with conduritol beta epoxide) to mimic the defect in Gaucher disease.
After NB-DNJ treatment of the WEHI 3B cells, the Glc-Cer content decreased in a dosedependent way, suggesting that the compound might have potential as a therapeutic . Healthy mice treated with the glucose analogue NB-DNJ exhibited 70% peripheral GSL depletion (Jeyakumar et al., 1999; Platt et al., 1997) . Clinical trials have recently been completed in type 1 Gaucher patients and are currently in progress in late onset Tay-Sachs disease, Niemann-Pick type C1 and type 3 Gaucher disease (Cox et al., 2000; Elstein et al., 2004) . NB-DNJ was administered during a 12-month period to patients suffering from nonneuronopathic type 1 Gaucher disease. The treatment was efficient as shown by a decrease in cell surface GM1 on leucocytes and a decrease in the volume of liver and spleen (Cox et al., 2000) . Importantly, the treatment was well tolerated by the patients and sustained improvement was seen over 36 months of therapy (Elstein et al., 2004) . The drug NB-DNJ (miglustat/Zavesca) was approved for clinical use in type 1 Gaucher disease in 2003. As
Gaucher disease does not involve the glycolipids, which are receptors for P fimbriae, the UTI susceptibility would not be expected to change in those patients. The UTI frequency in patients who receive NB-DNJ treatment has not been examined, however.
Effects of GSL inhibitors on bacterial attachment and the epithelial response in vitro
Based on the receptor specificity of P fimbriae, we examined if GSL inhibitors might prevent attachment and attenuate the disease process. We first used PDMP to inhibit GSL expression in A498 kidney epithelial cells in vitro. The receptor expression was reduced, as was the attachment of P fimbriated bacteria (Svensson et al., 1994) . PDMP treatment was limited to in vitro experiments, however, due to in vivo toxicity.
NB-DNJ and related compounds were subsequently used to block the expression of GSL receptors in vitro. NB-DNJ blocked the glycosylation of ceramide in kidney epithelial cells, as shown by thin layer chromatography of GSL extracts from the NB-DNJ treated cells. Total glycolipid extracts from cells grown in the presence or absence of NB-DNJ were separated by TLC and over-layed with 35 S labelled P fimbriated E. coli, to detect receptor active bands (Svensson et al., 2003) . There was a significant decrease in the globoseries of GSL as shown by autoradiography.
The consequence for bacterial attachment was examined using clinical E. coli isolates and NB-DNJ treatment reduced their binding. The specificity for P fimbriae was confirmed using a panel of recombinant strains that expressed either P or type 1 fimbriae, and the inhibition was shown to be specific for P fimbriated E. coli. Type 1 fimbriae bind to mannose expressing glycoproteins, which increased after NB-DNJ treatment, causing an increase in attachment of type 1 fimbriated E. coli to the treated epithelial cells. We conclude that receptor depletion by NB-DNJ treatment of epithelial cells can be achieved in vitro, and that this treatment reduces the attachment of P fimbriated E. coli.
NB-DNJ and GSL receptor depletion in vivo
NB-DNJ treatment was subsequently used to study the effect of receptor depletion in vivo in the murine experimental UTI model (Svensson et al., 2003) . The model mimics important aspects of disease pathogenesis in man. Bacteria are introduced into the bladder through a soft polyethylene catheter, bacteriuria is established, and the innate host response is triggered if the bacteria express virulence-associated lectins like P fimbriae. Non-adherent bacteria may establish bacteriuria, but do not break the inertia of the mucosal barrier or cause inflammation (Bergsten et al., 2004; Fischer et al., 2005) .
In vivo experiment were performed in 8 -12 weeks old female C3H/HeN mice. Mice were fed NB-DNJ (5mg/mouse/day) for two weeks prior to experimental UTI and a reduction of tissue glycolipid expression was observed. There was a marked reduction in tissue levels of the globoseries of GSL in treated mice as compared to the untreated controls (Svensson et al., 2003) . The effect of receptor depletion on bacterial persistence was quantified by bacterial counts in urine and tissues, before and at defined time point after bacterial installation. The number of P fimbriated bacteria was reduced in the kidneys and bladders of the NB-DNJ treated mice at all times, with the maximum difference after 6 hours (p< 0.028). Type 1 fimbriated E. coli, in contrast, showed higher bacterial counts in NB-DNJ treated compared to control mice, consistent with the increased attachment of this strain. The results demonstrate that GSL depletion by NB-DNJ treatment attenuates the virulence of P fimbriated E. coli.
Effects of NB-DNJ on E. coli induced mucosal inflammation.
Attaching, uro-pathogenic E. coli trigger the innate host response in the urinary tract mucosa and the epithelial cells amplify the response by secretion of cytokines and other mediators and by recruitment of inflammatory cells (Agace et al., 1992; Agace et al., 1993; Godaly et al., 1998; Hedges et al., 1990; Hedges et al., 1996) . The resulting mucosal inflammation is a cause of symptomatic disease, but also essential to clear the bacteria from the tissues. P fimbriated E. coli trigger a mucosal response both in mice and human patients (Hagberg et al., 1983; Wullt et al., 2001) . Human inoculation studies have demonstrated that attachment through the PapG tip adhesin enables the mucosa to recognise bacteria in the lumen and to activate mucosal inflammation (Bergsten et al., 2004) . P fimbriae thus fulfil the molecular Koch's postulated as independent virulence factors (Bergsten et al., 2004) . The host response is further controlled through Toll like receptor 4 (TLR4) signalling (Fischer et al., 2005; Frendeus et al., 2001) . The glycosphingolipid receptors for P fimbriae recruit TLR4 for transmembrane signalling and P fimbriae influence the adaptor proteins, which are involved downstream (Fischer et al., 2005) .
Strains carried by patients with asymptomatic bacteriuria rarely express P fimbriae, suggesting that it is possible to persist in the urinary tract without engaging the GSL receptors.
The effect of GSL depletion on the innate host response to P fimbriated E. coli was first examined in vitro, in PDMP treated human kidney cells. PDMP treatment lowered the cytokine response of epithelial cell lines to uropathogenic E. coli strains or recombinant P fimbriated strains but had no effect on the type 1 stimulated IL-6 response (Svensson et al., 1994) . The innate response to infection was subsequently examined in vivo. NB-DNJ treated and control mice were subjected to experimental infection with P fimbriated E. coli and the urine neutrophil numbers were used to quantify the innate response to infection. The epithelial chemo-attractants recruit inflammatory cells from the circulation to the mucosa and especially the neutrophils are essential to remove bacteria from the urinary tract (Haraoka et al., 1999; Shahin et al., 1987) . NB-DNJ treated mice showed a drastic reduction in urine neutrophil numbers following infection with P fimbriated E.
coli. This effect was P fimbriae dependent as shown by comparison with an isogenic strain lacking P fimbriae. The vector control strain did not trigger the innate host response, and there was no difference between NB-DNJ treated and control mice. The chemoattractant MIP-2 is a homologue of IL-8 and is involved in neutrophil-epithelial cell interactions in the urinary tract (Hang et al., 1999) . The secretion of MIP-2 into the urine was monitored in treated and control mice and a significant reduction of the MIP-2 response to P fimbriated E. coli was observed. In contrast, NB-DNJ treatment had no effect on the PMN or MIP-2 responses to the type 1 fimbriated strain (Svensson et al., 2003) . These in vivo results confirmed that GSL expression is important for the innate host response to P fimbriated E. coli.
Other approaches to the prevention of attachment
Many approaches have been taken to prevent disease by inhibition of attachment (Fig. 1) .
These include antibodies to the bacterial adhesins, which occupy the bacterial binding site and thus prevent the fimbriae from binding to the cellular receptor. The V. cholerae model was the first to show that antibodies could be used, and this was confirmed for Streptococci in the oral cavity, for uropathogenic E. coli, and for a variety of intestinal pathogens (Evans et al., 1984; Freter, 1969; Svanborg-Edén et al., 1976; Svanborg-Edén & Svennerholm, 1978; Williams & Gibbons, 1972) . Several veterinary vaccines were developed to prevent the attachment of entero-pathogens bearing the K88 or K99 adhesins, and were used quite extensively. Vaccines based solely on adhesins and the prevention of attachment have not been developed for human use, even though some currently used vaccines have effects on bacterial colonisation. For example, antibodies to the capsular polysaccharides of Haemophilus influenzae were found to protect both against the systemic and the mucosal phase of infection (Takala et al., 1993) .
Recently, a type 1 fimbrial vaccine was tested in patients with urinary tract infection but the results have not yet been published.
Soluble receptor analogues inhibit attachment by occupying the adhesin, thus preventing the bacteria from binding to the cell bound receptors. Early studies showed that mannose and derivatives of mannose inhibit the attachment of type 1 fimbriated E. coli (Duguid & Gillies, 1957; Ofek et al., 1977) . In vivo experiments showed that injecting methyl α-Dmannopyranoside into the bladder of the mouse blocked the colonization by type 1 fimbriated et al., 1979) . After the identification of the globoseries of GSL as receptors for P fimbriae, we showed that the soluble receptor inhibited attachment and reduced the persistence of fimbriated bacteria in vivo in the urinary tract (Svanborg-Edén et al., 1982) .
Shiga toxin binds the same family of GSL receptors and receptor analogues have been used to prevent the action of this toxin in vivo (Lingwood et al., 2000) .
Conclusion
This review summarises information on GSL biosynthesis inhibitors and urinary tract infection. N-alkylated imino sugars are orally available compounds, which inhibit the first step in the GSL biosynthetic pathway and have been used successfully to treat a GSL lysosomal storage disease (type 1 Gaucher). The drug NB-DNJ has undergone extensive animal and human testing, and offers a potential means of evaluating GSL depletion as an anti-microbial strategy. The strategy is to partially inhibit GSL biosynthesis in order to attenuate the infectivity of pathogens that rely on GSL receptors for their virulence. Using P fimbriated uro-pathogenic E. coli as an example, this study demonstrated that inhibitors of GSL synthesis offer an alternative to antibiotic treatment. The GSL inhibitor reduced receptor expression, leading to a reduction in the adherence of P fimbriated E. coli to epithelial cells.
The GSLs were also required as recognition receptors for the innate host response and receptor depletion reduced the epithelial chemokine response. Finally, NB-DNJ treatment caused a reduction in receptor expression in kidney tissue and prevented colonization by P fimbriated E. coli in vivo. The results suggest that NB-DNJ or similar compounds should be tested as prophylactic agents in patients with recurrent infections due to P fimbriated E. coli.
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